Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease, today announced new preclinical data demonstrating proof-of-concept for AB359 as a novel immunotherapy approach for chronic HBV. AB359 is Asher Bio’s CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infection. The data will be presented in a poster presentation at the American Association for the Study of Liver Disease (AASLD) 2022 Annual Meeting, being held in Washington, DC, on November 4-8, 2022.
“We are pleased to share these foundational preclinical data for AB359, demonstrating the broad applicability of our cis-targeting approach to potentially overcome key shortcomings of cytokine therapeutics and immunotherapies across a range of therapeutic areas, including oncology and now chronic viral infection,” said Andy Yeung, Ph.D., Chief Technology Officer and Co-founder of Asher Bio. “Chronic HBV is a major global health burden, which affects over 250 million people worldwide. Existing antiviral standard of care medicines, however, are indicated for only a subset of patients and offer low cure rates. Using our modular cis-targeting platform, we developed AB359 to selectively activate CD8+ T cells, which are important for clearing viruses, but become dysfunctional in patients with chronic HBV. We look forward to continuing to advance AB359 through preclinical development.”
CD8+ T cells have been shown to be involved in clearing some viral infections, including HBV. While functional HBV-reactive CD8+ T cells are detectable in HBV patients that clear viral infection, they are challenging to detect in patients with chronic HBV, suggesting the responses of CD8+ T cells against HBV antigens may be deficient in chronically infected patients
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?